✦ LIBER ✦

Oxaliplatin salvage for recurrent ovarian cancer: A single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity

✍ Scribed by Taylor, Sarah E.; Beck, Tiffany L.; Krivak, Thomas C.; Zorn, Kristin K.; Kelley, Joseph L.; Edwards, Robert P.

Book ID: 122287032
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 256 KB
Volume: 134
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2014.04.039

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Role of salvage chemotherapy with topote

Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study

✍ Ghamande, Sharad A.; Piver, M. Steven 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

## Background and Objectives: We assessed the role of salvage chemotherapy with topotecan and cisplatin in patients with platinum-and paclitaxel-resistant advanced and recurrent ovarian or primary peritoneal cancer, based on the reported in vivo and in vitro synergism between these two drugs. Meth

Multi-institutional phase 2 study of TLK

Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

✍ J.J. KAVANAGH; D.M. GERSHENSON; H. CHOI; L. LEWIS; K. PATEL; G.L. BROWN; A. GARC 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB